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Objectives: Literature reviews have identiﬁed a lack of consensus about the
deﬁnition of an exacerbation in CF. We sought to determine which exacerbation
deﬁnitions are most commonly used in CF clinical trials, and which signs/symptoms
are most commonly included in exacerbation deﬁnitions across all CF clinical trials.
Method: Eligible randomised trials were those in people with CF aged over 6 years,
where a sign/symptom-based deﬁnition was used to identify exacerbations as an
outcome. Eligible trials were identiﬁed from reference lists of Cochrane Reviews
in CF. Identiﬁed trials underwent citation tracking for further eligible trials. The
number of times a deﬁnition was used across all trials was tallied. The number of
times each symptom was included in any trial’s deﬁnition was also tallied.
Results: The searches identiﬁed 36 trials that had clearly speciﬁed the exacerbation
deﬁnition used. The most commonly used deﬁnitions were from the DNase trial
by Fuchs (1994), used in 11 trials; the US CFF Conference (1994), used in 6
trials; and the EPIC study (2009), used in 3 trials. The symptoms most commonly
used among all trials were: sputum (used in 36 trials), cough (35), spirometry (34),
weight/appetite (33), chest sounds (29), CXR changes (29), fever (27) and dyspnoea
(24). The remaining 13 signs/symptoms were each used in 18 or fewer trials.
Conclusion: Researchers may use these results to guide selection of a deﬁnition for
their research. Clinicians may use these results to consider whether the deﬁnition
used in a particular trial includes signs and symptoms that are generally accepted
as representing an exacerbation by most clinical trialists in CF.
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Background: Respiratory exacerbations (RE) are an important outcome measure
for research and clinical evaluation in Cystic Fibrosis (CF). Fuchs et al. proposed
a standard deﬁnition of RE for CF, but there is little data regarding the rate of
RE in CF. What evidence exists is inconsistent and fails to differentiate between
hospitalized or non-hospitalized patients.
Objectives: To determine the RE rate (RER) in Pediatric CF patients and in speciﬁc
CF pathologies.
Methods: A retrospective review of hospital admissions over a 1 year period (2010)
were evaluated using Fuchs’ RE criteria. These admissions were then examined for
factors which might affect RER.
Results: Of 124 patients, 76 admissions were observed. 17 for non respiratory
problems and 18 for 1st growth Pseudomonas. 41 admissions met RE criteria
(RER per patient: 41/124 = 0.33). 5 (4%) patients had 14 admissions due to ABPA
(RER= 2.8), 8 (6%) patients growing atypical mycobacteria, 2 admissions were
observed (RER= 0.25), in 5 (4%) patients colonised with Burkholderia cepacia
2 admissions were recorded (RER= 0.4). 12 admissions were seen in 4 (3%) patients
with severe disease (FEV1 <55%) (RER= 3.0), and 5 admissions in 7 (5%) patients
who were non-compliant (RER= 0.7). In 45 patients aged 6−18 yrs considered stable
5 admissions were observed (RER= 0.11).
Conclusions: RE rates vary depending on underlying infection and clinical status.
ABPA, atypical mycobacteria, B. cepacia and severe lung disease may increase risk
of RE. When reporting RE, it is important to deﬁne criteria for RE, but also the
CF population to which this measure is applied.
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Background: Progression of Cystic ﬁbrosis (CF) is characterized by bronchiecta-
sis (BE) and small airways disease. CT is the gold standard to monitor progression
of BE.
Hypothesis: Progression of BE results in a lower Health Related Quality of
Life (HRQoL), assessed by the Cystic Fibrosis Questionnaire − Revised (CFQ-R).
Objective: To evaluate associations between changes in BE and in HRQoL over
time.
Methods: Cohort study (July 2007–January 2012) in clinically stable children
and adolescents with CF, with two routine bi-annual chest CTs combined with
CFQ-Rs. CT scans were anonymized and randomly scored, using the CFCT-BE
score, expressing BE as a % of a maximum score. CFQ-R was completed by
children (aged 6−13 years) and their parents, or by adolescents (aged 14 years).
Score-range 0–100, higher scores indicate better HRQoL. For changes in CFCT-BE
score and CFQ-R respiratory domain scores, correlations, and to test the hypothesis
we respectively used Wilcoxon rank sum test, Student’s paired t-test, Spearman’s
correlation coefﬁcient, and a linear regression model, adjusted for age and gender.
Results: CF patients (n = 43): 31 children, 12 adolescents. In two years there
was a signiﬁcant change in CFCT-BE scores (p = 0.03), but not in CFQ-R scores
(p = 0.94). At T1 (p< 0.01, r = −0.47) and T2 (p = 0.01, r = −0.43) CFCT-BE scores
correlated to CFQ-R scores. Change in CFCT-BE scores did not correlate to change
in CFQ-R scores (p = 0.95).
Conclusion: BE score correlates to HRQoL. A modest progression of BE does not
result in impairment of HRQoL.
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The prevalence of MRSA infection is increasing in both the general population and
CF patients. We hypothesized that MRSA infection is associated with more severe
disease than MSSA infection in CF.
Objective: To compare clinical and functional features of CF patients chronically
colonized with MRSA and MSSA.
Material and Methods: Observational, cross-sectional study. Clinical reports
from patients attended at our Center during 2011 were reviewed. Age, gender,
genetics, BMI Z-score, FEV1, intravenous antibiotics were analyzed in chronically
SA infection, positive to MRSA or MSSA (more than 50% of at least 4 sputum
cultures during the year). Patients who were also colonized with Pseudomonas
aeruginosa or Burkholderia cepacia were excluded.
Results: From 110 patients, 33 (30%) were chronically infected with SA (39%
MRSA and 61% MSSA). From these, 10 patients in the MRSA group and 5 in
the MSSA group were colonized with other bacteria, so they were excluded. In the
MRSA group (7 females: 54%) the median current age was 8 years old (6 to 12
interquartile range) and in MSSA group (8 female: 40%) was 5 years old (3 to 10
interquartile range). In the MRSA group 46% had p.F508del mutation homozygous
while 55% in MSSA group. The median BMI Zscore was −0.15 (−0.7 to 0.1) in the
MRSA group and −0.06 (−0.4 to 0.3) in the MSSA group. (p =NS). The median
FEV1 was 75% (70 to 88) of predictive values in MRSA group and 99% (85 to 105)
in MSSA group (p = 0.03). There were 1 (1 to 2) iv antibiotic courses in MRSA
group and 0 (0 to 1) in MSSA group (p = 0.01).
Conclusion: CF patients chronically colonized with MRSA had a diminished
pulmonary function and required more intravenous antibiotic courses.
